EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Alivus Life Sciences's enterprise value is ₹121,790 Mil.
Alivus Life Sciences's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 was ₹23,869 Mil. Therefore, Alivus Life Sciences's EV-to-Revenue for today is 5.10.
The historical rank and industry rank for Alivus Life Sciences's EV-to-Revenue or its related term are showing as below:
BOM:543322'
s EV-to-Revenue Range Over the Past 10 Years
Min: 2.14 Med: 3.5 Max: 6.92
Current: 5.11
During the past 7 years, the highest EV-to-Revenue of Alivus Life Sciences was 6.92. The lowest was 2.14. And the median was 3.50.
BOM:543322's EV-to-Revenue is ranked worse than 74.72% of 973
companies
in the Drug Manufacturers industry
Industry Median: 2.43
vs BOM:543322: 5.11
Alivus Life Sciences EV-to-Revenue Historical Data
The historical data trend for Alivus Life Sciences's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Alivus Life Sciences's EV-to-Revenue
For the Drug Manufacturers - Specialty & Generic subindustry, Alivus Life Sciences's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alivus Life Sciences's EV-to-Revenue Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Alivus Life Sciences's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Alivus Life Sciences's EV-to-Revenue falls into.
Alivus Life Sciences's current Enterprise Value is ₹121,790 Mil.
Alivus Life Sciences's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹23,869 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alivus Life Sciences (BOM:543322) EV-to-Revenue Explanation
Alivus Life Sciences's share price for today is ₹1036.55.
Alivus Life Sciences's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹194.25.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alivus Life Sciences EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Alivus Life Sciences's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Alivus Life Sciences Ltd, formerly Glenmark Life Sciences Ltd develops, manufactures, and supplies high-quality active pharmaceutical ingredients for cardiovascular disease, central nervous system disease, pain management, diabetes, gastrointestinal disorders, anti-infectives, and other therapeutic areas.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BOM:543322 has been successfully added to your 